Biostatistics
-
AstraZeneca’s HICKORY Trial Fails Primary Endpoint Due to Design Mismatch
AstraZeneca’s Phase 3 HICKORY trial for efzimfotase alfa failed its primary endpoint, highlighting critical gaps in rare disease clinical trial feasibility.
AstraZeneca’s Phase 3 HICKORY trial for efzimfotase alfa failed its primary endpoint, highlighting critical gaps in rare disease clinical trial feasibility.